

EFFICACY OF TEGOPRAZAN IN PATIENTS WITH FUNCTIONAL DYSPESIA; A PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY

Young-Hoon Youn

UEG Week Copenhagen 2023

Poster

Oesophagus

October 15, 2023

A prospective multicenter trial of 173 functional dyspepsia patients found that tegoprazan 50mg once daily for 8 weeks provided satisfactory symptom relief in 86.7% of patients.

KEY POINTS

- The rate of satisfactory relief of dyspeptic symptoms was 74.6% at 4 weeks and 86.7% at 8 weeks, with complete symptom relief achieved in 15.0% and 24.9% of patients respectively.
- Symptom resolution rates were significantly higher at 8 weeks compared to 4 weeks (p less than 0.001 for satisfactory relief, p equals 0.003 for complete relief).
- Mean scores on the NDI-K and GERD-HRQL questionnaires significantly decreased at 8 weeks.
- Efficacy was not influenced by functional dyspepsia subtypes or Helicobacter pylori status, and no serious adverse events or deaths occurred during the study.
- This material would be most relevant to gastroenterologists considering potassium-competitive acid blockers for functional dyspepsia management.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflif.eu/search/d/8c4d8754-743b-11ee-a106-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.